ClinicalTrialsFinder
SuspendedPhase 1ACTRN12612000952842

Bioavailability of orally administered gamma-glutamylcysteine

Bioavailability study to determine whether a single oral dose of gamma-glutamylcysteine (GGC) sodium salt can transiently increase glutathione content of the white blood cells and brain tissue of healthy volunteers.

Sponsor

University of New South Wales

Enrollment

18 participants

Start Date

Mar 25, 2013

Study Type

Interventional

Conditions

This bioavailability trial represents an initial investigation in healthy volunteers to determine the potential of gamma-glutamylcysteine (GGC) to augment cellular glutathione levels. Glutathione depletion is associated with numerous age related disorders.

Summary

Gamma glutamylcysteine (GGC) is commonly found in many foods, such as garlic and whey, which are anecdotally associated with numerous health benefits. GGC can potentially be used by the body to synthesise the commonly termed “master antioxidant” glutathione, which is responsible for protecting our cells from oxidative stress and for the elimination of toxins. As we age our body’s capacity to produce sufficient glutathione progressively declines leaving us vulnerable to many age related diseases and disorders. In this study, we will investigate whether oral administered GGC can be of benefit in increasing the glutathione content in blood cells in young. mature and aged populations.

Eligibility

Sex: Both males and femalesMin Age: 20 YearssMax Age: 80 Yearss

Inclusion Criteria2

  • Aged 20 - 80 years, reasonable health, non-smoker, non alcoholic, not pregnant, and not surgically fitted with metal medical devices (e.g. pace makers, Cochlear implants) .
  • Healthy body weight [body mass index (BMI) 18.5 - 25 kg/m2]

Exclusion Criteria1

  • smokers, alcoholics, any illnesses requiring regular medication

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

On separate days with a one week washout, participants will receive double blinded single oral doses of gamma-glutamylcysteine (GGC) in the range of 250 mg to 4g (placebo control glucose) . Participan

On separate days with a one week washout, participants will receive double blinded single oral doses of gamma-glutamylcysteine (GGC) in the range of 250 mg to 4g (placebo control glucose) . Participants will range from 18 to 20 years, with the only exclusions being smokers, pregnancy, and metal medical implants (MRI). Glutathione levels will be monitored periodically for up to 7 hours following administration by the taking of blood samples (lymphocyte glutathione content) and/or by MRI/MRS (brain tissue content).

Locations(1)

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12612000952842